Радиотехника
Издательство РАДИОТЕХНИКА

"Издательство Радиотехника":
научно-техническая литература.
Книги, журналы издательств ИПРЖР, РС-ПРЕСС, САЙНС-ПРЕСС


Тел.: +7 (495) 625-9241

::Журналы
::Книги
 

Ангиогенные факторы при раке яичников (обзор)

Ключевые слова:

Д.Н. Кушлинский, И.В. Терешкина, К.П. Лактионов, Л.В. Адамян


Обзор литературы посвящен анализу клинической значимости ключевых факторов неоангиогенеза у больных раком яичников, их связи с основными клинико-морфологическими характеристиками заболевания, прогнозам и возможностям антиангиогенной терапии.
Список литературы:
  1. Hanahan D., Weinberg R. Hallmarks of cancer: the next generation // Cell. 2011. V. 144.
    P. 646 – 674.
  2. Mendiola M., Barriuso J., Redondo A. et al.Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma // PLoS ONE. 2008. V. 3. Р.(on line)e4051.
  3. Ramakrishnan S., Subramanian I.V., Yokoyama Y., Geller M. Angiogenesis in normal and neoplastic ovaries // Angiogenesis. 2005. V. 8. Р. 169 – 182.
  4. Kumaran G.C., Jayson G.C., Clamp A.R. Antiangiogenic drugs in ovarian cancer // Br. J. Camcer. 2009. V. 100. Р. 107.
  5. Menendez D., Inga A., Snipe J. et al. A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1 // Mol. Cell Biol. 2007. V. 27. Р. 2590 – 2600.
  6. Gospodarowicz D., Abraham J.A., Schillng J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells // Proc. Natl. Sci. USA. 1989. V. 86. Р. 7311 – 7315.
  7. Keck P.J., Hauser S.D., Krivi G. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF // Science. 1989. V. 246.
    Р. 1309 – 1312.
  8. Fraser H.M., Wilson H., Rudge J.S., Wiegand S.J. Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function // J. Clin. Endocrinol. Metab. 2005. V. 90. Р. 1114 – 1122.
  9. Carmeliet P., Ferreira V., Breier G. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele // Nature. 1996. V. 380. Р. 435 – 439.
  10. Neufeld G., Cohen T., Gengrinovitch S. et al. Vascular endothelial growth factor (VEGF) and its receptors // FASEB J. 1999. V. 13. Р. 9 – 22.
  11. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis // Breast Cancer Res. Treat. 1995. V. 36. № 2.
    Р. 127 – 137.
  12. Folkman J.Anti-angiogenesis: new concept for therapy of solid tumours // Ann. Surg. 1972.
    V. 175. Р. 409 – 416.
  13. Fong G.H., Rossant J., Gertsenstein M.,
    Breitman M.L.
    Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium // Nature. 1995. V. 376.
    Р. 66 – 70.
  14. Folkman J.What is the evidence that tumours are angiogenesis dependent? // J. Natl. Cancer Inst. 1990. V. 82. Р. 4 – 6.
  15. Obermair A., Kurz C., Czerwenka K. et al. Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival // Int. J. Cancer. 1995. V. 62. Р. 126 – 131.
  16. Folkman J. Tumor angiogenesis // Adv. Cancer Res. 1985. V. 43.
    Р. 175 – 230.
  17. Spannuth W.A., Nick A.M., Jennings N.B. et al. Functional significance of VEGFR-2 on ovarian cancer cells // Int. J. Cancer. 2009. V. 124. Р. 1045 – 1053.
  18. Pulaski H.L., Spahlinger G., Silva I.A. et al.Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer // J. Transl. Med. 2009. V. 7. P. 49
    (Published online 2009, June 19).
  19. Folkman J., Long D.M., Becker F.F. Growth and metastasis of tumor in organ culture // Cancer. 1963. Р. 453-467.
  20. Gimbrone M.A, Leapman S.B., Cotran R.S., Folkman J. Tumor angiogeneses: iris neovascularization at a distance from experimental intraocular tumors // J. Natl. Cancer Inst. 1973. V. 50.
    Р. 219 – 228.
  21. Pintucci G., Bikfalvi A., Klein S., Rifkin D.B. Angiogenesis and the fibrinolytic system // Semin. Thromb. Hemost. 1996. V. 22. № 6. Р. 517 – 524.
  22. Григорьева И.Н., Соломко Э.Ш., Степанова Е.В., Харатишвили Т.К. Ингибирование васкулогенной мимикрии – новый подход к противоопухолевой антиангиогенной терапии с использованием нанопрепаратов // Российский биотерапевтический журнал. 2010. Т. 9. № 3. С. 9.
  23. Gordon M.S., Mendelson D.S., Kato G. Tumor angiogenesis and novel antiangiogenetic strategies // Int. J. Cancer. 2009. V. 126. № 8. P. 1777 – 1787.
  24. Иванцов А.О., Мацко Д.Е. Возможности иммуногистохимического исследования в диагностике опухолей // Практическая онкология. 2011. Т. 12. № 4. C. 185 – 193.
  25. Haubner R. Tracer for angiogenesis imaging: potential targets and recent progress // J. Labell. Compounds and Radiopharm. 2003. V. 4.
    Suppl. 1. P. 33 – 34.
  26. Alc’azar J.L. Tumor angiogenesis assessed by threedimensional power Doppler ultrasound in early, advanced and metastatic ovarian cancer: a preliminary study // Ultrasound in Obstetrics and Gynecology. 2006. V. 28. № 3. P. 325 – 329.
  27. Thomassin-Naggara I., Bazot M., Darai E. et al. Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis // Radiology. 2008. V. 248. № 1. P. 148 – 159.
  28. Nagengast W.B., de Vries E.G., Hospers G.A. et al.In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft // J. Nuclear Medicine. 2007. V. 48. N 8. P. 1313 – 1319.
  29. Kut C., Mac Gabhann F., Popel A.S. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer // Br. J. Cancer. 2007.
    V. 97. P. 978 – 985.
  30. Merritt W.M., Lin Y.G., Spannuth W.A. et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth // J. Natl. Cancer Inst. 2008. V. 100. № 5. P. 359 – 372.
  31. Martin L., Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition // J. Clin. Oncol. 2007. V. 25. N 20. P. 2894 – 2901.
  32. Hefler L.A., Mustea A., Konsgen D. et al. Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer // Clin. Cancer Res. 2007. V. 13. P. 898 – 901.
  33. Buckanovich R.J., Sasaroli D., O’Brien-Jenkins A. et al. Tumor vascular proteins as biomarkers in ovarian cancer // J. Clin. Oncol. 2007. V. 25. № 7. P. 852 – 861.
  34. Высоцкий М.М., Дигаева М.А., Крюк Ю.В. и др. Сывороточные маркеры у больных новообразованиями яичников // В материалах XVII Российского национального конгресса «Человек и лекарство» (Москва, 12-16 апреля 2010 г.). М. 2010. C. 70.
  35. HonokiK., TsijiuchiT., SasakiY. etal.Differential expression of cytokines in rat osteosarkoma and malignant fibrous histiocytoma celle lines induced by 4-(hydroxyamino) quinoline -1-oxide // Mol. Carcinog. 2002. V. 33. № 2. P. 81 – 87.
  36. Mizukami Y., Jo W.-S., Duerr E.-M. et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells // Nature Medicine. 2005. V. 11. № 9. P. 992 – 997.
  37. Schultheis A.M., Lurje G., Rhodes K.E. et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab // Clin. Cancer Res. 2008.
    V. 14. № 22. P. 7554 – 7563.
  38. Shaw T.J., Vanderhyden B.C. AKT mediates the prosurvival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate // Gynecologic Oncology. 2007.
    V. 105. № 1. P. 122 – 131.
  39. Duhoux F.P., Machiels J.-P. Antivascular Therapy for Epithelial Ovarian Cancer // J. Oncol. 2009. V. 2010. P. 1 – 16.
  40. Kamba T., Tam B.Y., Hashizume H. et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature // Am. J. Physiol. Heart Circ. Physiol. 2006. V. 290. P. 560 – 576.
  41. Степанова Е.В., Полушкина И.Н., Дбар Ж.Н. и др. Молекулярно-биологические маркеры рака яичников // Российский биотерапевтический журнал. 2002. № 4. C. 14 – 20.
  42. Zhang A., Meng L., Wang Q. et al. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2 // Oncology Reports. 2006. V. 15. № 4. P. 831 – 836.
  43. Takada Y., Ye X., Simon S. The integrins // Genome Biol. 2007. V. 8. P. 215.
  44. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis // J. Clin. Oncol. 2005. V. 23. № 5. P. 1011 – 1027.
  45. Park J.E., Keller G.-A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differantional deposition into the subepithelial extracellular matrix and bioactivity of ECM-bound VEGF // Mol. Biol. Cell. 1993. V. 4. P. 1317 – 1326.
  46. Alon T., Hemo I., Itin A. et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of permaturity // Nat. Med. 1995.
    V. 1. P. 1024 – 1028.
  47. Benjamine L.E., Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrowal // Proc. Natl. Acad. Sci. USA. 1977. V. 94. P. 8761 – 8766.
  48. Герштейн Е.С. Молекулярные маркеры опухолей в клинике - история, настоящее и будущее. В материалах конгресса «Национальные дни лабораторной медицины России» (4-6 октября 2011г.) // Клиническая лабораторная диагностика. 2011. № 9. C. 14.
  49. Piccino R., Puopolo M., Rigault De Longrais I.A. et al. Fattori di crescita e carcinoma epiteliale ovarico // Minerva ginecol. 2002. V. 54. № 1. P. 33 – 52.
  50. Byrne A.T., Ross L., Holash J. et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model // Clin. Cancer Res. 2003. V. 9. P. 5721 – 5728.
  51. Trinh X.B., Tjalma W.A.A., Vermeulen P.B. et al. The VEGF pathway and the AKT/mTOR/ p70S6K1 signalling pathway in human epithelial ovarian cancer // Br. J. Cancer. 2009. V. 100. № 6. P. 971 – 978.
  52. Menendez D., Inga A., Snipe J. et al. A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1 // Mol. Cell Biol. 2007. V. 27. P. 2590 – 2600.
  53. Schmidt M., Kammerer U., Segerer S. et al. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF // Eur. J. Obstet. Gynecol. Reprod. Biol. 2008. V. 139. P. 72 – 78.
  54. Artini P.G., Ruggiero M., Monteleone P. et al. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors // Pharmacother. 2008. V. 62. P. 373 – 377.
  55. Lerner-Marmarosh N., Miralem T., Gibbs P.E.M., Maines M.D. Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling // Proc. Natl. Acad. Sci. USA. 2008. V. 105.
    P. 6870 – 6875.
  56. Yamomoto S., Konishi I., Mandai M. et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels // Br. J. Cancer. 1997. V. 76. № 9. P. 1221 – 1227.
  57. Полушкина И.Н., Степанова Е.В., Дбар Ж.Н. Молекулярно-биологи­ческие маркеры, характеризующие апоптоз, пролиферацию и ангиогенез при раке яичников // Вестник РОНЦ им. Н.Н.Блохина РАМН. 2004. № 4.
    C. 60 – 64.
  58. Дбар Ж.Н. Экспрессия ангиогенных факторов при раке яичников III-IV стадии: Автореф. дисс. …канд. мед. наук. М. 2003.
  59. HataK., WatanabeY., NakaiH. etal. Экспрессия гена фактора роста эндотелия сосудов (VEGF) при эпителиальном раке яичника: подходы к анти-VEGF терапии // Int. J. CancerRes. Treat. 2011. V. 31. P. 731 – 738.
  60. Высоцкий М.М., Дигаева М.А., Крюк Ю.В. и др. Сывороточные маркеры у больных новообразованиями яичников // В материалах XVII Российского национального конгресса «Человек и лекарство» (Москва, 12-16 апреля 2010 г.). М. 2010. C. 70.
  61. Дигаева М.А., Бахоева К.А., Крюк Ю.В. и др. Фактор роста эндотелия сосудов и растворимый Fas в сыворотке крови больных новообразованиями яичников // В материалах Международной конференции «Молекулярная медицина и биобезопасность» (Москва 10-11 ноября 2009 г.). М. ММА им. Сеченова И.М. 2009. C. 81 – 82.
  62. PalmerJ.E., SantCassiaL.J., IrwinC.J. etal. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary // Int. J. Gynecol. Pathol. 2007. V. 26. № 4. P. 395 – 403.
  63. Raspollini M.R., Amunni G., Villanucci A. et al. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma // Int. J. Gynecol. Cancer. 2004. V. 14. № 5. P. 815 – 823.
  64. O’Toole S.A., Sheppard B.L., Laios A. et al. Potential predictors of chemotherapy response in ovarian cancer—how do we define chemosensitivity? // Gynecologic Oncology. 2007. V.104. № 2.
    P. 345 – 351.
  65. Duncan T.J., Al-Attar A., Rolland P. et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? // Clin. Cancer Res. 2008. V. 14. № 10. P. 3030 – 3035.
  66. Alvarez R.H., Kantarjian H.M., Cortes J.E. Biology of platelet-derived growth factor and its involvement in disease // Mayo Clinic Proceedings. 2006. V. 81. № 9. P. 1241 – 1257.
  67. Ostman A., Heldin C. PDGF receptors as targets in tumor treatment // Advances in Cancer Research. 2008. V. 97. P. 247 – 274.
  68. Henriksen R., Funa K., Wilander E. et al. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms // Cancer Res. 1993. V. 53. № 18. P. 4550 – 4554.
  69. Schoell W., Pieber D., Reich O. et al. Tumor of angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis // Cancer. 1997. V. 80. P. 2257 – 2262.
  70. Hollingsworth H.C., Kohn E.C., Steinberg S.M. et al. Tumor angiogenesis in advanced stage ovarian carcinoma // Am. J. Pathol. 1995. V. 147. № 1. P. 33 – 41.
  71. Барышников А.Ю., Степанова Е.В., Личиницер М.Р. Оценка ангиогенеза опухолей // Успехи современной биологии. 2000. Т. 120. № 6. C. 599 – 604.
  72. Луценко С.В., Киселев С.М., Фельдман Н.Б., Северин С.Е. Молекулярные механизмы ангиогенеза в физиологических и патологических процесса // В кн.: Введение в молекулярную медицину под ред. М.Пальцева. М.:Медицина. 2004. C. 446 – 495.
  73. Rosen L. Antiangiogenic strategies and agents in clinical trials // The Oncologist. 2000. V. 5.
    P. 20 – 27.
  74. Nimeiri H.S., Oza A.M., Morgan R.J. et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia // Gynecol. Oncol. 2008. V. 110. № 1. P. 49 – 55.
  75. Matulonis U.A., Berlin S., Ivy P. et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube and peritoneal cancer // J. Clin. Oncol. 2009. V. 27. № 33. P. 5601 – 5606.
  76. Tew W., Colombo N., Ray-Caquard I. et al.
    VEGF-Trap for patients with recurrent platinum resistant epithelial ovarian cancer // J. Clin. Oncol. 2008. V. 25. № 18S. abstract 5508.
  77. Dhanabal M., Ramchandran R., Waterman M. J. et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma // J. Biol. Chem. 1999. V. 274.P. 11721 – 11726.
  78. O`Reilly M.S., Holmgren L., Shing Y. et al. Angiostatin:a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis
    lung carcinoma // Cell. 1994. V. 79. P. 315-328.
  79. Curran S., Murray G.J. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis // Eur. J. Cancer. 2000. V. 36. № 13. P. 1621 – 1630.
  80. Wedge S.R., Ogilvie D.J., Dukes M. et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy // Cancer Res. 2000. V. 60. № 4. P. 970 – 975.
  81. Kris M.G., Benowitz S.I., Adams S. et al.Успехи клинической онкологии 2010: наиболее значимые достижения в лечении, профилактике и скрининге онкологических заболеваний. Сообщение Американского общества клинической онкологии (ASCO) // J. Clin. Oncol. 2011. V. 5. № 1. P. 80 – 101.
  82. Sher I., Adham S.A., Petrik J., Coomber B.L. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis // Int. J. Cancer. 2009. V.124. Р.553 – 561.
  83. Spannuth W.A., Nick A.M., Jennings N.B. et al. Functional significance of VEGFR-2 on ovarian cancer cells // Int. J. Cancer. 2009. V. 124. P. 1045 – 1053.
  84. Matei D., Chang D.D., Jeng M.-H. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through amechanism dependent on platelet-derived growth factor receptor αand Akt inactivation // Clin. Cancer Res. 2004. V. 10. № 2. P. 681 – 690.
  85. Matei D., Emerson R.E., Schilder J. et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial // Cancer. 2008. V. 113. № 4. P. 723 – 732.
  86. Bergers G., Hanagan D. Models of resistance to anti-angiogenic therapy // Nat. Rev. Cancer. 2008. V. 8. P. 592 – 603.
  87. Ebos J.M., Lee C.R., Cruz-Munoz W. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis // Cancer Cell. 2009. V. 15. P. 232 – 239.

© Издательство «РАДИОТЕХНИКА», 2004-2017            Тел.: (495) 625-9241                   Designed by [SWAP]Studio